Search

Your search keyword '"Fostira, F."' showing total 345 results

Search Constraints

Start Over You searched for: Author "Fostira, F." Remove constraint Author: "Fostira, F."
345 results on '"Fostira, F."'

Search Results

2. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

3. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers.

4. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome

5. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

6. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome

7. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

10. Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience

13. Article chek2 pathogenic variants in greek breast cancer patients: Evidence for strong associations with estrogen receptor positivity, overuse of risk-reducing procedures and population founder effects

14. Clinical significance of germline cancer predisposing variants in unselected patients with pancreatic adenocarcinoma

15. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

16. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

17. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature Communications, (2021), 12, 1, (1078), 10.1038/s41467-020-20496-3).

18. Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078)).

19. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

20. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

21. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

22. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.

23. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

24. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

25. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

26. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

28. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

29. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

30. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

31. One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene

32. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects

33. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections

34. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

35. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

36. The spectrum of fancm protein truncating variants in European breast cancer cases.

37. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness.

38. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

39. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.

40. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses.

41. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

42. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

43. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

44. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

45. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

46. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

47. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

48. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

49. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

50. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Catalog

Books, media, physical & digital resources